Tue, Sep 30, 2014, 2:18 AM EDT - U.S. Markets open in 7 hrs 12 mins

Recent

% | $
Quotes you view appear here for quick access.

Regenerx Biopharmaceuticals Inc. Message Board

  • donker3 donker3 Apr 3, 2013 12:22 PM Flag

    Regenerx Patent #8,399,412

    TB4 on gingivitis:

    "Although antimicrobial mouthrinses are available, none contain ingredients that control the tissue inflammation associated with gingivitis. Thymosin beta 4 (T.beta..sub.4) is a naturally occurring anti-inflammatory agent that is non-toxic to humans. T.beta..sub.4 is a highly stable, water-soluble peptide that could be used in the formulation of a ***novel non-prescription mouthrinse*** with combined antimicrobial, anti-inflammatory, and anti-apoptotic properties that would be of high impact with regards to oral health."

    "Thymosin beta 4 (T.beta..sub.4), a water-soluble, stable, non-toxic peptide, and other peptide agents as described herein, are particularly useful as mouthrinses that combat the inflammatory responses of oral mucosal cells to pathogenic bacteria. The formulation of a mouthrinse with combined antimicrobial and anti-inflammatory properties ***available over-the-counter*** will have a direct impact on the oral health of the public."

    The Donk added the stars. Note non-prescription and over the counter....

    Regenerx about to be the 'Jan Marini' of TB4 mouthwash.....

    Read that patent in whole....

    On the new eye patent I think there's also a chance for over the counter eye drops.....

    The Donker

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Going over the counter with eye drops or mouthwash would provide an immediate cashflow and new found credibility if they can partner with one of the big name brands. The market is there and Fink alluded to the pending short term catalyst when talking about reason for new convert.
      But, what is the possible reason for "hiding" the names of the 2 other new investors. ? Who would really care unless these are well known names in the bio space that might attract too much attention and cause a bounce in price here. Fink&co don't seem to want any price movement(as donk has point out with the hiding of new patents) until some kind of deal is announced. That figures with doing just enough finance to keep company alive but not enough to encourage real investors. Whatever, its all one big unknown for now.

      • 1 Reply to bocamp1
      • more and more pieces to the profitability puzzle...with any of this news released we would be well off single digits...I can remember the exact same scenario with Scln and bloeble said we are not in the stock business...we are here to run a bio pharm,,, when it was time though they knew enough to do a buyback, move up price, collect about a cool mil each in option payouts... same carrot is now in front of JJ and the board... they act like they are only concerned with the bio pharm issues but their real goal is paydirt... We should all be stuffing our pockets with shares right now... I am sure this oral over the counter use will be the catalyst for ST to throw in the real money, just like scln and sngx and before that qcor...

    • Several years ago I posted that the 'Steins were peddling TB4 off the back of their wagon, with the claim that it would cure dandruff, gout, and gingivitis.

      One down, two to go ! ! !

 
RGRX
0.1291-0.0002(-0.15%)Sep 29 1:52 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.